LUND, Sweden, Aug. 11, 2016 (GLOBE NEWSWIRE) --
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from both the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
- Positive results concerning laquinimod were presented at the 68th AAN Annual Meeting (American Academy of Neurology), held in Vancouver, Canada, on April 15-21, 2016
Tasquinimod
- The complete study results of the Phase 3 10TASQ10 study have been published in the Journal of Clinical Oncology
- Out-licensing activities are continuing
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
SEK M | Q2 | Q1-Q2 | Full Year | ||
2016 | 2015 | 2016 | 2015 | 2015 | |
Net sales | 3.9 | 3.2 | 7.9 | 6.1 | 16.3 |
Operating loss | -14.5 | -70.1 | -30.6 | -127.5 | -177.9 |
Loss for the period | -15.5 | -71.4 | -32.3 | -129.3 | -193.5 |
Loss per share, before and after dilution (SEK) | -0.17 | -0.79 | -0.36 | -1.44 | -2.15 |
Cash and cash equivalents (at the end of the period) | 57.4 | 186.6 | 103.6 |
-
Refocusing of the company is completed, operating costs reduced by 71% (SEK 95.2 M) compared with 2015
-
The number of employees will be reduced from 56 (June 2015) to 17 by the end of the third quarter of 2016
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46 19 20 44 |
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 05 |
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim Report January - June 2016 http://hugin.info/1002/R/2034058/757619.pdf
HUG#2034058